Primary Profile

IMBiotechnologies Ltd

IMBiotechnologies Ltd

IMBiotechnologies Ltd

Advanced Technology Centre, 113 - 9650 - 20 Ave NW
Edmonton, Alberta
T6N 1G1

Advanced Technology Centre, 113 - 9650 - 20 Ave NW
Edmonton, Alberta
T6N 1G1

(780) 945-6609

(780) 987-0941

Click here

IMBiotechnologies Ltd

IMBiotechnologies Ltd develops embolic devices used to treat hypervascular tumors including malignant (e.g. liver cancer) and benign (e.g. uterine fibroids) tumors.

Company Details

No

334512 - Measuring, Medical and Controlling Devices Manufacturing

541710 - Research and Development in the Physical, Engineering and Life Sciences

Manufacturer / Processor / Producer

Product / Service / Licensing

Out-License (Offering): Occlusin 500 Artificial Embolization Device
Occlusin 500 Artificial Embolization Device (OCL 500) is a biodegradable embolic agent used to treat hypervascular tumors such as liver cancer and uterine fibroids. OCL 500 consists of microspheres that are delivered by catheter to the blood vessels feeding a tumor(s) where they induce localized clot formation leading to tumor starvation and regression.


Contact Information


Michael Stewart
Title: Chief Executive Officer
Area of Responsibility: Management Executive
Telephone: (780) 945-6609
Fax: (780) 987-0941

Irwin Griffith
Title: Chief Operating Officer
Area of Responsibility: Management Executive
Telephone: (780) 493-0561
Fax: (780) 987-0941